A novel SPECT/CT acquisition method can accurately detect radiopharmaceutical biodistribution in a convenient manner for prostate cancer patients, opening the door for more personalized treatment.

Evaluation of de novo oligometastatic prostate cancer patients managed with radiation therapy: A multi-institution, real-world dataset. This is an ASCO Meeting Abstract from the 2025 ASCO ...

Bone SPECT/CT imaging – the integration of functional single photon emission computed tomography with anatomical computed tomography – represents a significant advancement in the evaluation of foot ...

Reston, VA (October 13, 2025)--A new fast and convenient approach to scintigraphy-based monitoring allows physicians to efficiently and reliably assess prostate cancer progression or regression during ...

BEDFORD, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc., the leading radiopharmaceutical-focused company dedicated to helping clinicians Find, Fight, and Follow disease to deliver ...

Prognostic value of quantitative PSMA-PET parameters during chemotherapy in prostate cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This abstract does not ...